Cyclerion Therapeutics, Inc.
CYCN
$3.00
-$0.01-0.33%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.99M | 2.07M | 2.86M | 2.17M | 2.08M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.99M | 2.07M | 2.86M | 2.17M | 2.08M |
| Cost of Revenue | 1.65M | 959.00K | 496.00K | 229.00K | 278.00K |
| Gross Profit | 340.00K | 1.12M | 2.36M | 1.95M | 1.80M |
| SG&A Expenses | 7.07M | 6.09M | 5.99M | 5.70M | 5.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.72M | 7.05M | 6.49M | 5.93M | 5.55M |
| Operating Income | -6.73M | -4.97M | -3.63M | -3.76M | -3.47M |
| Income Before Tax | -5.28M | -3.53M | -2.20M | -1.95M | -2.94M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.28 | -3.53 | -2.20 | -1.95 | -2.94 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.28M | -3.53M | -2.20M | -1.95M | -2.94M |
| EBIT | -6.73M | -4.97M | -3.63M | -3.76M | -3.47M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.37 | -1.18 | -0.76 | -0.74 | -1.16 |
| Normalized Basic EPS | -1.13 | -1.00 | -0.74 | -0.73 | -0.73 |
| EPS Diluted | -2.13 | -1.18 | -0.76 | -0.74 | -1.16 |
| Normalized Diluted EPS | -1.13 | -1.00 | -0.74 | -0.73 | -0.73 |
| Average Basic Shares Outstanding | 14.31M | 12.66M | 11.39M | 10.70M | 10.13M |
| Average Diluted Shares Outstanding | 14.31M | 12.66M | 11.39M | 10.70M | 10.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |